1.Cheng's Juanbi Decoction Inhibits Rheumatoid Arthritis Pathology by Blocking the WTAP-Wnt7b-Wnt/β-Catenin Signaling Axis
Yajie WU ; Wenbo XU ; Meiling YUAN ; Xinyue ZHOU ; Yikang CAI ; Huibo CAO ; Qiangjun DUAN ; Tongxiang TAO ; Chenggui MIAO
Journal of Sichuan University (Medical Sciences) 2025;56(5):1260-1272
Objective Cheng's Juanbi Decoction(CSJBD)is a classic traditional Chinese medicine formula for treating rheumatoid arthritis(RA),exhibiting significant clinical efficacy,but the underlying mechanisms remain unclear.We investigated whether CSJBD inhibited RA pathology by blocking the WTAP-Wnt7b-Wnt/β-catenin signaling axis using a collagen-induced arthritis(CIA)mouse model and fibroblast-like synoviocytes(FLSs)derived from RA patients(RA FLSs)and examined the underlying mechanisms.Methods We conducted in vivo experiments.Male C57BL/6 mice weighing 17 to 20 g were used to establish the CIA model.The mice were assigned to 6 groups,including the normal group,the model(CIA)group,the model+CSJBD-L(8.1 g/kg)group,the model+CSJBD-M(16.2 g/kg)group,the model+CSJBD-H(32.4 g/kg)group,and the model+leflunomide(LEF)(0.05 mg/10 g)group,with 10 mice in each group.CSJBD was administered twice daily via gastric gavage,while LEF was administered once daily via gastric gavage,for a duration of 28 days.We also conducted in vitro experiments.RA FLSs were assigned to 4 groups,including the RA FLSs+CSJBDS-L group receiving 10%CSJBDS-containing serum,the RA FLSs+CSJBDS-M group receiving 15%CSJBDS-containing serum,the RA FLSs+CSJBDS-H group receiving 20%CSJBDS-containing serum,and the RA FLSs+NC group(negative control).To study whether WTAP regulated Wnt7b,RA FLSs were divided into the RA FLSs group,the RA FLSs+si-WTAP#3 group,the RA FLSs+si-WTAP#3+Wnt7b-OE group,and the RA FLSs+si-WTAP#3+Wnt7b-NC group.To study the underlying mechanism by which CSJBT affected RA FLSs,RA FLSs were divided into the RA FLSs group,the RA FLSs+CSJBDS-M group,the RA FLSs+CSJBDS-M+Wnt7b-OE group,and the RA FLSs+CSJBDS-M+NC group.We used ultra-high performance liquid chromatography(UPLC)to identify and quantify key monomer compounds from CSJBD as quality criteria for CSJBD preparation.Bioinformatics,CCK-8,RT-qPCR,Western blot,immunofluorescence,and related methods were employed to assess the therapeutic efficacy and underlying mechanisms of CSJBD in treating RA.Results According to the UPLC analysis,ferulic acid,osthole,mulberroside A,notopterol,and gentiopicroside were identified as quality control standards for the preparation of CSJBD formula.CSJBD improved RA pathology in CIA mice,reduced the levels of interleukin(IL)-6,IL-1β,IL-8,and tumor necrosis factor-α(TNF-α)in their serum,and decreased the expression of RA pathological genes MMP3 and fibronectin,with the difference between groups being statistically significant.Bioinformatics analysis suggested that CSJBD might inhibit RA pathology by suppressing the Wnt/β-catenin signaling pathway through Wnt7b.Experimental results showed that the expression of WTAP and Wnt7b was significantly increased in RA.After knocking down WTAP,the expression of Wnt7b was significantly reduced,and the Wnt/β-catenin signaling pathway was also inhibited,with the difference between groups being statistically significant(P<0.05),confirming that WTAP regulated the pathway via Wnt7b.According to experimental verification,CSJBD significantly inhibited the Wnt/β-catenin signaling pathway and the proliferation of RA FLSs.Wnt7b overexpression reversed the inhibitory effect of CSJBD on the Wnt/β-catenin signaling pathway and the proliferation of RA FLSs,indicating that Wnt7b is the direct target of CSJBD.Conclusion CSJBD inhibits RA pathology by blocking the WTAP-Wnt7b-Wnt/β-catenin signaling axis,with Wnt7b identified as a direct therapeutic target of CSJBD.
2.Effect of emergency "zero channel" process on improving efficiency of intravenous thrombolysis in stroke
Yiyu HONG ; Qun WANG ; Qian WANG ; Shuo WANG ; Hua XIE ; Xuexia MAI ; Yucun ZHU ; Qiangjun XU ; Rongrong LIAO
Chinese Journal of Neuromedicine 2022;21(2):176-179
Objective:To explore the effect of emergency "zero channel" process on improving the efficiency of intravenous thrombolysis in stroke.Methods:Fifty-eight acute ischemic stroke patients admitted to our hospital from January 2020 to December 2020 were enrolled into experimental group; another 58 acute ischemic stroke patients admitted to our hospital from January 2019 to December 2019 and matched with age and gender were selected as control group. "Green channel" process was adopted for patients in the control group, and optimized "zero channel" process (moving the working passageway forward to the ambulance) was implemented for patients in the experimental group. Door to rescue room time (DRRT), door to consultation time (DCT), door to laboratory examination completion time (DLECT), door to CT report time (DCRT), and door to needle time (DNT) were used to evaluate the times of emergency treatment. The thrombolytic effect of the two groups was compared by evaluating the recanalization rate of occluded vessels and thrombolytic efficiency. Modified Rankin scale (mRS) was used to evaluate the prognoses 6 months after treatment in both groups, and mRS scores≤2 was defined as good prognosis.Results:The DCRT, DCT and DNT in the experimental group were significantly shorter than those in the control group ( P<0.05); the compliance rate of DNT≤60 min in the experimental group was significantly higher as compared with that in the control group ( P<0.05). The immediate recanalization rate of occluded vessels in the experimental group and control group was 60.3% and 27.6%, and the thrombolytic efficiency was94.83% and 82.76%; significant differences were noted between the two groups ( χ2=12.633, P<0.001; χ2=4.245, P=0.039). The good prognosis rate of the experimental group and control group was 36.2% and 15.5%, respectively, after 6 months of follow-up ( χ2=4.016, P=0.041). Conclusion:Emergency "zero channel" can further shorten DCT, DCRT, and DNT, and improve the efficiency of thrombolysis and prognoses of acute ischemic stroke patients.
3.Association of coagulation factor Ⅶ with the risk of myocardial infarction in the Chinese
Qiangjun CAI ; Jilin CHEN ; Huili MA ; Jie SONG ; Minilu XU
Chinese Medical Journal 2000;113(12):1059-1063
Objective To elucidate the association of plasma factor Ⅷ oagulant activity(FⅦc)with me risk of myocardial infarction (MI) and to assess the influence of factor Ⅶ gene Mspl polymorphism and lipid metabolism on FⅦc in the Chinese. Methods A total of 137 patients with angiographically confirmed MI and 125 healthy individuals were evaluated retrospectively. Plasma FⅦC was measured by one-stage prothrombin time,and FⅦ genotype was determined after Mspl digestion of polymerase chain reaction-amplified genomic DNA.Serum lipidlevels were assessed by routine methods.Results MI patients had significantly higher levels of FⅦc (119.5%±22.7% vs 99.9%±21.8%,P<0.01) and total serum cholesterol (5.80±1.06mmol/L vs 5.53±1.08 mmol/L, P<0.05) than controls, but only FⅦc independently correlated with the risk of MI (OR=1.04, P<0.01). There were no significant differences in FⅦ genotype or allele frequency between patients and controls (P>0.05).Subjects with the Gln353 allele were associated with significantly lower FⅦc levels than Arg353homozygotes (99.7%±19.3% vs 111.4%±24.6%,P<0.05). Serum triglyceride was positively correlated with plasma FⅦc in both control(r=0.25, P<0.01)and case (r=0.87, P<0.01) groups, but this correlation was restricted to Arg/Arg genotypa (r=0.68, P<0.01).A significant correlation of total serum cholesterol with FⅦc only appeared in Arg/Arg homozygotes (r=0.17, P<0.01). Conclusions Our findings support the role of plasma FⅦc as a risk factor for MI in Chinese. Plasma triglyceride and FⅦ gene Mspl pclymorphism are two independent determinants of FⅦc. Assay of this polymorphism will be helpful in determining who will benefit most from lipid-lowing therapy.

Result Analysis
Print
Save
E-mail